NASDAQ: STIMNeuronetics Inc Stock
$1.31+0.07 (+5.65%)
Updated Jun 11, 2026
STIM Price
$1.31
Fair Value Price
N/A
Market Cap
$91.16M
52 Week Low
$0.80
52 Week High
$4.85
P/E
-2.43x
P/B
6.87x
P/S
0.67x
PEG
N/A
Dividend Yield
N/A
Revenue
$151.64M
Earnings
-$37.11M
Gross Margin
48%
Operating Margin
-18.7%
Profit Margin
-24.5%
Debt to Equity
8.17
Operating Cash Flow
-$13M
Beta
1.45
Next Earnings
Aug 4, 2026
Ex-Dividend
N/A
Next Dividend
N/A
STIM Overview
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine STIM's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
C
STIM
Ranked#37 of 44
Ranked#37 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $23.66 | A | |
| $129.55 | B | |
| $16.39 | B |
Be the first to know about important STIM news, forecast changes, insider trades & much more!
STIM News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how STIM scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
STIM is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
STIM is poor value based on its book value relative to its share price (6.87x), compared to the US Diagnostics & Research industry average (3.54x)
P/B vs Industry Valuation
STIM is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more STIM due diligence checks available for Premium users.
Valuation
STIM price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.43x
Industry
16.18x
Market
13.95x
STIM price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
6.87x
Industry
3.54x
STIM is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
STIM's financial health
Profit margin
Revenue
$34.5M
Net Income
-$10.8M
Profit Margin
-31.3%
STIM's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
STIM's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$125.4M
Liabilities
$108.4M
Debt to equity
8.17
STIM's short-term assets ($47.18M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
STIM's long-term liabilities ($80.10M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
STIM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
STIM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.4M
Investing
-$172.0k
Financing
-$5.6M
STIM's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
STIM vs Diagnostic & Research Stocks
Neuronetics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.